CAMBRIDGE COGNITION HOLDINGS PLC

Declaration of Voting Results & Voting Rights Announcements • Jun 27, 2025

National Storage Mechanism | Additional information

RNS Number : 7888O

Cambridge Cognition Holdings PLC

27 June 2025

27 June 2025

Cambridge Cognition Holdings plc

(" Cambridge Cognition" , the "Company" or the "Group")

Result of AGM

Cambridge Cognition Holdings plc, the brain health software group specialising in digital health products that advance brain health research and treatment, held its Annual General Meeting ("AGM") earlier today at the registered office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all resolutions put forward were duly passed.

Proxy votes were received in respect of 67.6% of the Company's issued share capital. The votes cast were as follows:

	Resolution	Votes For	Percent of votes cast For	Votes Against	Percent of votes cast Against	Votes Withheld
1	To approve the 2024 Report and Accounts	28,372,450	100%	-	-	-
2	To approve the 2024 Directors' Remuneration Report1	28,346,127	99.91%	25,315	0.09%	1,008
3	To approve the Directors' Remuneration Policy1	28,346,127	99.91%	25,315	0.09%	1,008
4	To re-appoint the auditors	28,359,763	99.99%	3,500	0.01%	9,187
5	To authorise the directors to set the auditors' remuneration	28,370,475	100%	-	-	1,975
6	To re-elect Steven Powell as a director	28,369,043	100%	-	-	3,407
7	To re-elect Richard Bungay as a director	24,074,907	100%	-	-	4,297,543
8	To re-elect Stuart Gall as a director	28,371,018	100%	-	-	1,432
9	To re-elect Debra Leeves as a director	24,074,907	100%	-	-	4,297,543
10	To re-elect Nick Rodgers as a director	28,371,018	100%	-	-	1,432
11	To elect Jon Kempster as a director	28,371,018	100%	-	-	1,432
12	Authority to allot shares	28,340,996	99.89%	30,446	0.11%	1,008
13	Authority to disapply pre-emption rights2	28,323,483	99.83%	47,959	0.17%	1,008
14	Authority to purchase own shares on the market2	24,925,895	99.84%	39,143	0.16%	3,407,412

Notes

1.  Indicates an advisory vote.

2.  Indicates a Special Resolution requiring 75% of votes cast to be carried.

Enquiries:

Cambridge Cognition Holdings plc	Tel: 012 2381 0700
Rob Baker, Joint Managing Director and Chief Operating Officer	press@camcog.com
Panmure Liberum Limited (NOMAD and Joint Broker)	Tel: 020 7886 2968
Freddy Crossley / Will Goode / Mark Rogers	(Corporate Finance)
Rupert Dearden	(Corporate Broking)
Dowgate Capital Limited (Joint Broker)	Tel: 020 3903 7715
David Poutney / Amber Higgs
Hudson Sandler (Financial PR and IR ) Dan de Belder / Hattie Dreyfus / Jackson Redley	Tel: 020 7796 4133 cog@hudsonsandler.com

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGPKOBBDBKDPAB